Evidence map›Paper›PMID 18984741›Full record

ArticleDiabetes2009

Idd loci synergize to prolong islet allograft survival induced by costimulation blockade in NOD mice.

Julie Mangada, Todd Pearson, Michael A Brehm, Linda S Wicker, Laurence B Peterson, Leonard D Shultz, David V Serreze, Aldo A Rossini, Dale L Greiner

Open access · hybridAbstract read
In one paragraph

Article in Diabetes, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. The NOD Mouse Beyond Autoimmune Diabetes.Frontiers in immunology · 2022
    Review
  2. Article
  3. Article
  4. Use of nonobese diabetic mice to understand human type 1 diabetes.Endocrinology and metabolism clinics of North America · 2010
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Julie MangadaProgram in Immunology and Virology, the University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Todd Pearson
Michael A Brehm
Linda S Wicker
Laurence B Peterson
Leonard D Shultz
David V Serreze
Aldo A Rossini
Dale L Greiner
University of Massachusetts Chan Medical School · USJackson Laboratory · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USUniversity of Cambridge · GB

Funding

ROLE OF CBL AND PHOSPHATIDYLINOSITOL 3-KINASE IN CD40 SIGNALINGP01DK053006 · NIDDK · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MORDES, JOHN PETER · 1997 to 2007
$8.9M
Diabetogenic Role of MHC Class I Alleles in NOD MiceR01DK046266 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V · 2000 to 2018
$7.2M
VIRUS-INDUCED IMMUNOPATHOLOGYR01AR035506 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI WELSH, RAYMOND M · 1986 to 2008
$3.3M
ANTIGEN PRESENTING CELL DEFECTS IN AUTOIMMUNE DIABETESR01DK051090 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V · 1996 to 2009
$3.0M
INTERCELLULAR SIGNALS AND INTESTINAL AGANGLIONOSISR01DK052530 · NIDDK · UNIVERSITY OF WASHINGTON · PI KAPUR, RAJ P. · 1997 to 2000
$241k
SINGLE CYCLE SIV PARTICLES--A NOVEL VACCINE STRATEGYR21AI042669 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI ZHANG, LINQI · 1997 to 1998
–
DIABETOGENIC ROLE OF H-2G7 CLASS I ALLELES IN NOD MICER29DK046266 · NIDDK · JACKSON LABORATORY · PI SERREZE, DAVID V. · 1993 to 1998
–
NIAID NIH HHS AI42669NIAMS NIH HHS AR35506NIAMS NIH HHS R01 AR035506NIDDK NIH HHS DK46266NIDDK NIH HHS DK51090NIDDK NIH HHS DK52530NIDDK NIH HHS DK53006NIDDK NIH HHS P01 DK053006NIDDK NIH HHS R01 DK046266NIDDK NIH HHS R01 DK051090NIDDK NIH HHS R29 DK046266Wellcome Trust 061859
6 · The paper itself

Abstract

objectiveNOD mice model human type 1 diabetes and are used to investigate tolerance induction protocols for islet transplantation in a setting of autoimmunity. However, costimulation blockade-based tolerance protocols have failed in prolonging islet allograft survival in NOD mice. RESEARCH DESIGN AND

methodsTo investigate the underlying mechanisms, we studied the ability of costimulation blockade to prolong islet allograft survival in congenic NOD mice bearing insulin-dependent diabetes (Idd) loci that reduce the frequency of diabetes.

resultsThe frequency of diabetes is reduced in NOD.B6 Idd3 mice and is virtually absent in NOD.B6/B10 Idd3 Idd5 mice. Islet allograft survival in NOD.B6 Idd3 mice treated with costimulation blockade is prolonged compared with NOD mice, and in NOD.B6/B10 Idd3 Idd5, mice islet allograft survival is similar to that achieved in C57BL/6 mice. Conversely, some Idd loci were not beneficial for the induction of transplantation tolerance. Alloreactive CD8 T-cell depletion in (NOD x CBA)F1 mice treated with costimulation blockade was impaired compared with similarly treated (C57BL/6.H2(g7) x CBA)F1 mice. Injection of exogenous interleukin (IL)-2 into NOD mice treated with costimulation prolonged islet allograft survival. NOD.B6 Idd3 mice treated with costimulation blockade deleted alloreactive CD8 T-cells and exhibited prolonged islet allograft survival.

conclusionsIl2 is the Idd3 diabetes susceptibility gene and can influence the outcome of T-cell deletion and islet allograft survival in mice treated with costimulation blockade. These data suggest that Idd loci can facilitate induction of transplantation tolerance by costimulation blockade and that IL-2/Idd3 is a critical component in this process.

Indexed as

AnimalsAntibodies, MonoclonalCD40 LigandCytotoxicity, ImmunologicDiabetes Mellitus, Type 1Flow CytometryGraft SurvivalIslets of LangerhansIslets of Langerhans TransplantationKiller Cells, NaturalMiceMice, CongenicMice, Inbred C3HMice, Inbred NODTransplantation, HomologousAntibodies, MonoclonalCD40 Ligand

Identifiers

PMID18984741
PMCPMC2606867
OpenAlexW2126453856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.